Clinical trials: GnRH Antagonist
Infertility
FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled ovarian hyperstimulation in a GnRH-antagonist…
- Trial name
- FAST (NCT01969201)
- Testing
- Urofollitrophin, Follitrophin alpha
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 710 people
- Sponsor
- IBSA Institut Biochimique SA
Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants.
- Trial name
- ELARIS EM-I (NCT01620528)
- Testing
- elagolix
- Volunteers
- 872 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
BPH
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with…
- Trial name
- NCT00527488
- Testing
- Degarelix
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Ferring Pharmaceuticals
Endometriosis
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in pre-menopausal women.
- Trial name
- NCT01760954
- Testing
- Elagolix
- Volunteers
- 506 people
- Sponsor
- AbbVie
Infertility
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation…
- Trial name
- MEGASET HR (NCT02554279)
- Testing
- menotropin, recombinant FSH
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Infertility, Female
Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
The main purpose of this clinical research study is to investigate if degarelix can synchronise the growth of the egg sacs in the ovaries and if degarelix has any effect on the lining of the womb.
- Trial name
- NCT00434122
- Testing
- Degarelix mid-luteal, 2.5 mg
- Where
- 4 sites in Belgium, Czechia and 1 more
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Infertility
MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer
The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles…
- Trial name
- MEGASET (NCT00884221)
- Testing
- Highly purified menotrophin, Recombinant FSH
- Where
- 25 sites in Belgium, Czechia and 5 more
- Volunteers
- 749 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL).
- Trial name
- NCT02083185
- Testing
- Relugolix, Leuprorelin
- Where
- 23 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
Endometriosis
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study…
- Trial name
- NCT02143713
- Testing
- Elagolix
- Volunteers
- 496 people
- Sponsor
- AbbVie
Infertility
MENOPUR® Versus FOLLISTIM®
To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF)…
- Trial name
- NCT00802360
- Testing
- Menotropin, Progestrone vaginal insert, follitropin beta
- Where
- 7 sites in United States
- Volunteers
- 173 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT)…
- Trial name
- PRONOUNCE (NCT02663908)
- Testing
- Degarelix, Leuprolide
- Where
- 133 sites in United States, Canada and 10 more
- Volunteers
- 545 people
- Sponsor
- Ferring Pharmaceuticals
In Vitro Fertilization
Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)
The objective of the trial is to assess the non-immunogenicity and safety of corifollitropin alfa (also known as Org 36286, SCH 900962 and MK-8962) in participants undergoing repeated COS cycles using a multiple dose GnRH…
- Trial name
- Trust (NCT00696878)
- Testing
- Corifollitropin alfa, FSH, GnRH antagonist
- Volunteers
- 682 people
- Sponsor
- Organon and Co
Infertility, Female
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long…
- Trial name
- BEYOND (NCT03809429)
- Testing
- FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE)
- Where
- 16 sites in Austria, Denmark and 5 more
- Volunteers
- 437 people
- Sponsor
- Ferring Pharmaceuticals
Infertility
Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
The success of assisted reproductive technologies (ART) is critically dependent on optimizing protocols for controlled ovarian stimulation to provide adequate numbers of good quality oocytes and embryos.
- Trial name
- Xpect (NCT00778999)
- Testing
- Marvelon
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Endometriosis
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
- Trial name
- ELARIS EM-II (NCT01931670)
- Testing
- Elagolix
- Volunteers
- 815 people
- Sponsor
- AbbVie